Replies to post #808 on Biotech Values

[mskatiescarletohara]

Another heavyweight joins GENR. I like the way this company has been able to attract solid executive management with impressive resumes in the past few months. I suspect Mr. Imasogie will be an important asset to the BOD regarding negotiations with potential partners or acquisitions. Only 20K in options, I am a little surprised at the low number, I expected more given his experience.

I agree about NO GSK collaboration, that would be a conflict of interest. Scratch them off the list of potential collaborators.

katie...

[Biowatch]

The new director

>>Osagie O. Imasogie is VP & Director, GSK Ventures, a new group created within GlaxoSmithKline that is responsible for the external value maximization of various GSK R&D assets that will not be further progressed. Osagie has led the Ventures Team in over 20 transactions that generated a portfolio of significant value for GSK.<<

It sounds as if his job at GSK is to license or partner out promising products that GSK does not wish to pursue. I assume many of these go to small companies. It seems like he would have excellent experience overseeing small companies like GENR.

>>Osagie has been the General Counsel for the Manufacturing, International and Generic Drug Divisions of DuPont Merck.<<

DuPont Merck was a joint venture between DuPont and Merck created because DuPont had experience in making pharmaceuticals, but needed Merck's expertise at getting things through the FDA and on the market. They brought several drugs to the market. Subsequently, DuPont bought out Merck's stake in the venture, then BMY bought DuPont.

[masterlongevity]

Hey Dew, I gave myself up on the IMCL yahoo MB